Display Settings:

Format

Send to:

Choose Destination
Arthritis Res. 2000;2(3):165-8. Epub 2000 Mar 27.

Anti-TNF-alpha therapy as a clinical intervention for periprosthetic osteolysis.

Author information

  • 1Department of Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA. Edward.Schwarz@URMC.Rochester.edu

Abstract

Aseptic loosening of total joint arthroplastics due to periprosthetic osteolysis is a frequent cause of implant failure. The absence of clinical interventions to arrest or prevent this complication limits the use of total joint replacement especially in younger patients. Here we review recent studies implicating tumor necrosis factor (TNF)-alpha in periprosthetic osteolysis and the rationale for clinical studies of anti-TNF therapy and other interventions for periprosthetic loosening.

PMID:
11094423
[PubMed - indexed for MEDLINE]
PMCID:
PMC129996
Free PMC Article

Images from this publication.See all images (1)Free text

Figure 1
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Write to the Help Desk